The abundance of pathologically determined stromal TILs is known to be a surrogate marker of response to neoadjuvant chemotherapy in breast cancer.33,34 Therefore, we expected that intratumoral TILs assessed by our TIL score would be associated with complete response to neoadjuvant chemotherapy in the HER2-positive and TNBC subtypes, which is almost always the case in morphologically evaluated stromal TILs. The gene discussed is ERBB2; the disease is breast cancer.